Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710033 · ClinicalTrials.gov registry record · Phase 1
A Study Of CP-690,550 In Stable Kidney Transplant Patients
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01710033 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT01710033, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients. In Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts of subjects. After Stage 1, one dose level was to be selected for dosing in an expanded cohort in Stage 2.
Interventions
- DRUG Placebo
- DRUG CP-690,550 5 mg BID
- DRUG CP-690,550 15 mg BID
- DRUG CP-690,550 30 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-09 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710033
The ClinicalTrials.gov registry entry for NCT01710033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01710033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710033 about?
NCT01710033 is a clinical study titled "A Study Of CP-690,550 In Stable Kidney Transplant Patients". This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients. In Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts of subjects. After Stage 1, one dos...
What is the current status of trial NCT01710033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2003-09. Estimated completion is 2005-04.
What interventions are being tested in trial NCT01710033?
The interventions under investigation include: Placebo (DRUG), CP-690,550 5 mg BID (DRUG), CP-690,550 15 mg BID (DRUG), CP-690,550 30 mg BID (DRUG).
Who is sponsoring clinical trial NCT01710033?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.